Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24566133 | 0.86 | PLAU (0.32) | PLAUELANE | |
| SCHEMBL25687914 | 0.82 | NSD1 (0.31) | — | |
| SCHEMBL23957768 | 0.79 | — | — | |
| SCHEMBL25812427 | 0.75 | AKR1C3 (0.36) | — | |
| SCHEMBL18390417 | 0.75 | MAP2K1 (0.36) | — | |
| SCHEMBL26621219 | 0.75 | L3MBTL1 (0.35) | — | |
| SCHEMBL31393206 | 0.71 | — | — | |
| SCHEMBL24566152 | 0.71 | PLAU (0.30) | PLAUELANE | |
| SCHEMBL23509916 | 0.70 | NPC1 (0.35) | — | |
| SCHEMBL23501194 | 0.70 | ALDH1A1 (0.38) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4688778-A1 | 1H-PYRROLO[2,3-B]PYRIDIN-4-YL]-2-OXOPYRROLIDINE-3-CARBONITRILE DERIVATIVES AS TYROSINE KINASE 2 (TYK2) INHIBITORS FOR THE TREATMENT OF INFLAMMATORY DISEASES | Biogen MA Inc. (US) | 2026-02-11 | — | — | EP | disclosed |
| EP-4301468-B1 | FGFR3 INHIBITOR COMPOUNDS | LILLY CO ELI (US) | 2025-09-03 | — | — | EP | disclosed |
| US-20250122196-A1 | FGFR3 INHIBITOR COMPOUNDS | ELI LILLY AND COMPANY | 2025-04-17 | — | — | US | disclosed |
| US-12209086-B2 | FGFR3 inhibitor compounds | ELI LILLY AND COMPANY (US) | 2025-01-28 | — | — | US | disclosed |
| WO-2024211696-A1 | 1H-PYRROLO[2,3-B]PYRIDIN-4-YL]-2-OXOPYRROLIDINE-3-CARBONITRILE DERIVATIVES AS TYROSINE KINASE 2 (TYK2) INHIBITORS FOR THE TREATMENT OF INFLAMMATORY DISEASES | BIOGEN MA INC. (US) | 2024-10-10 | — | — | WO | disclosed |
| US-20240190870-A1 | FGFR3 INHIBITOR COMPOUNDS | LOXO ONCOLOGY, INC. | 2024-06-13 | — | — | US | disclosed |
| US-20240083900-A1 | PYRAZOLO[1,5-A]PYRAZINE DERIVATIVES AS BTK INHIBITORS | BIOGEN MA INC. (US) | 2024-03-14 | — | — | US | disclosed |
| US-11878976-B2 | FGFR3 inhibitor compounds | ELI LILLY AND COMPANY (US) | 2024-01-23 | — | — | US | disclosed |
| EP-4244223-A1 | PYRAZOLO[1,5-A]PYRAZINE DERIVATIVES AS BTK INHIBITORS | Biogen MA Inc. (US) | 2023-09-20 | — | — | EP | disclosed |
| US-20230095122-A1 | FGFR3 INHIBITOR COMPOUNDS | LOXO ONCOLOGY, INC. | 2023-03-30 | — | — | US | disclosed |
| WO-2022104079-A1 | PYRAZOLO[1,5-A]PYRAZINE DERIVATIVES AS BTK INHIBITORS | BIOGEN MA INC. (US) | 2022-05-19 | — | — | WO | disclosed |
| WO-2022104079-A1 | PYRAZOLO[1,5-A]PYRAZINE DERIVATIVES AS BTK INHIBITORS | BIOGEN MA INC. (US) | 2022-05-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11878976-B2 | FGFR3 inhibitor compounds | FGFR3, FGFR1, FGFR2 | PLAU 3857/4885ELANE 2638/4885 |
| US-12209086-B2 | FGFR3 inhibitor compounds | FGFR3, FGFR1, FGFR2 | PLAU 3857/4885ELANE 2638/4885 |
| US-20240083900-A1 | PYRAZOLO[1,5-A]PYRAZINE DERIVATIVES AS BTK INHIBITORS | BTK, SYK, LYN | PLAU 3163/4885ELANE 2949/4885 |
| US-20240190870-A1 | FGFR3 INHIBITOR COMPOUNDS | FGFR3, FGFR1, FGFR2 | PLAU 3857/4885ELANE 2638/4885 |
| US-20250122196-A1 | FGFR3 INHIBITOR COMPOUNDS | FGFR3, FGFR1, FGFR2 | PLAU 3857/4885ELANE 2638/4885 |
| US-20230095122-A1 | FGFR3 INHIBITOR COMPOUNDS | FGFR3, FGFR1, FGFR2 | PLAU 3857/4885ELANE 2638/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.